ReviewSeminars in nuclear medicine2011
The next generation of positron emission tomography radiopharmaceuticals in oncology.
Review in Seminars in nuclear medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- The diagnostic performance ofBMC medical imaging · 2017Pooled it
- Integrated Proteomics and Metabolomics Analysis in Pregnant Rat Hippocampus After Circadian Rhythm Inversion.Frontiers in physiology · 2022Article
- Cold Kit Labeling: The Future ofFrontiers in medicine · 2022Review
- PET Imaging of the Natural Killer Cell Activation Receptor NKp30.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Article
- IntratumoralEJNMMI research · 2019Article
- Review
- Prospective ofContrast media & molecular imaging · 2018Review
- Production of novel diagnostic radionuclides in small medical cyclotrons.EJNMMI radiopharmacy and chemistry · 2018Review
- Evolution of lymphoma staging and response evaluation: current limitations and future directions.Nature reviews. Clinical oncology · 2017Article
- Evaluation of a novel sodium borocaptate-containing unnatural amino acid as a boron delivery agent for neutron capture therapy of the F98 rat glioma.Radiation oncology (London, England) · 2017Article
- Clinical PET-MR Imaging in Breast Cancer and Lung Cancer.PET clinics · 2016Review
- Diagnostic Accuracy of 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography in the Evaluation of Carcinoma of Unknown Primary.Molecular imaging and radionuclide therapy · 2016Article
- p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET.Bioconjugate chemistry · 2015Article
- Fully-automated synthesis of 16β-(18)F-fluoro-5α-dihydrotestosterone (FDHT) on the ELIXYS radiosynthesizer.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine · 2015Article
- A nuclear chocolate box: the periodic table of nuclear medicine.Dalton transactions (Cambridge, England : 2003) · 2015Review
- Alternative chelator for ⁸⁹Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO).Journal of medicinal chemistry · 2014Article
- MR-detectable metabolic consequences of mitogen-activated protein kinase kinase (MEK) inhibition.NMR in biomedicine · 2014Article
- Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.European journal of nuclear medicine and molecular imaging · 2014Article
- 18F-glutathione conjugate as a PET tracer for imaging tumors that overexpress L-PGDS enzyme.PloS one · 2014Article
- Prospective of ⁶⁸Ga-radiopharmaceutical development.Theranostics · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Although (18)F-fluorodeoxyglucose ((18)F-FDG) is still the most widely used positron emission tomography (PET) radiotracer, there are a few well-known limitations to its use. The last decade has seen the development of new PET probes for in vivo visualization of specific molecular targets, along with important technical advances in the production of positron-emitting radionuclides and their related labeling methods. As such, a broad range of new PET tracers are in preclinical development or have recently entered clinical trials. The topics covered in this review include labeling methods, biological targets, and the most recent preclinical or clinical data of some of the next generation of PET radiopharmaceuticals. This review, which is by no means exhaustive, has been separated into sections related to the PET radionuclide used for radiolabeling: fluorine-18, for the labeling of agents such as FACBC, FDHT, choline, and Galacto-RGD; carbon-11, for the labeling of choline; gallium-68, for the labeling of peptides such as DOTATOC and bombesin analogs; and the long-lived radionuclides iodine-124 and zirconium-89 for the labeling of monoclonal antibodies cG250, and J591 and trastuzumab, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.